Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARLHA-2
2024-514829-36-00Phase 3Authorised
- Sponsor
- Unicancer
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of apalutamide in prostate adenocarcinoma (2 arms), sponsored by Unicancer. Primary endpoint: Progression-free survival at 5 years. Planned start Jul 2024; status: authorised.
02
Drugs
apalutamide
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on 2024-514829-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514829-36-00.